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Abstract
Background Chemotherapy may increase postoperative
morbidity and mortality after liver surgery. Especially
bevacizumab, a monoclonal antibody against vascular
endothelial growth factor (VEGF), could have a detri-
mental effect. To assess the impact of neoadjuvant bev-
acizumab on clinical outcome after hepatectomy for
colorectal liver metastases (CRLMs) this case-matched
control study was initiated.
Methods The multicentric data collection was performed
in the Swiss HPB Center of the University Hospital
Zurich (CH), the Department of Digestive Surgery and
Transplantation Strasbourg (F), and the Division of Hepato-
biliary-pancreatic surgery of ‘‘Josep Tureta’’ Hospital
Girona (E). Consecutive patients operated onbetween July
2005 and December 2007 due to CRLMs who received
neoadjuvant chemotherapy were assessed. Patients were
divided in two groups: group A had neoadjuvant chemo-
therapy with bevacicumab, and group B had it without
bevacizumab.
Results No differences in overall morbidity (56 vs. 40%
in the bevacizumab and control groups, respectively,
p = 0.23) or mortality could be documented. Similarly, the
incidence of severe postoperative complications was not
statistically different between the bevacizumab and control
groups (31 and 18%, respectively, p = 0.31). Wound
complications were comparable (11% in the bevacizumab
group compared and 9% in the control group, p = 1.00).
However, bevacizumab was associated with a significantly
decreased incidence of postoperative hepatic insufficiency
(7 vs. 20%, p = 0.03).
Conclusions No impact on the incidence or severity of
complications by bevacizumab could be shown. Bev-
acizumab may even reduce the incidence of liver failure
after liver surgery.
Introduction
Systemic chemotherapy prior to resection of colorectal
liver metastases (CRLMs) is increasingly advocated by
modern interdisciplinary teams in many countries. How-
ever, the benefit and safety of this strategy remains con-
troversial [1–5].
Bevacizumab (Bev) is a monoclonal antibody against vas-
cular endothelial growth factor (VEGF) with antiangiogenic
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properties. Bev is typically used in combination with other
chemotherapeutic agents such as oxaliplatin, irinotecan,
leucovorin, and 5-fluorouracil (5-FU) for treatment of
patients with CRLMs [6–8]. In addition to its direct antian-
giogenic effects, Bev may also improve the delivery of
chemotherapy by altering tumor vasculature and decreasing
the elevated interstitial pressure in tumors [6, 7, 9, 10]. It is
therefore postulated that Bev treatment may result in a high
rate of disease stability, with a substantial impact on survival
and progression-free survival in the setting of metastatic
colorectal cancer [11–13].
Chemotherapeutic agents that inhibit tumor growth also
have inherent side effects on healthy tissue. For instance,
oxaliplatin and irinotecan may alter the histomorphologic
characteristics of the liver [14–19], and Bev has been
associated with bleeding, thrombosis, impaired wound
healing, and liver regeneration [20]. The effect of preop-
erative Bev with chemotherapeutic agents (particularly
oxaliplatin and irinotecan) on posthepatectomy complica-
tions remains under debate [17, 21]. Three studies from
North America failed to show an increase in postoperative
complications upon adding Bev to preoperative chemo-
therapy [22–24]. However, the study by D’Angelica et al.
[22] included only 16 patients treated with Bev; and the
studies by Reddy et al. [23] and Kesmodel et al. [24] had
relevant methodologic shortcomings due to lack of statis-
tical adjustments and matching of patient groups. Also, all
studies were carried out in the United States, where the
chemotherapy is predominantly oxaliplatin-based.
To address a putative negative impact of the use of Bev
on postoperative outcome, we designed a European mul-
ticentric study in three established surgical centers that
maintained well documented databases. We evaluated
consecutive patients treated with an oxaliplatin- or irino-
tecan-based chemotherapy regimen, with and without Bev,
regarding the incidence and severity of postoperative
complications including evidence of hepatic insufficiency.
Owing to the relatively long half-life of Bev (*20 days)
[8, 25], we also focused on the interval between the last
dose of Bev and the initiation of surgery—what we called
the ‘‘drug holiday’’—on postoperative outcome.
Methods
Study design
Patients who underwent liver resection owing to CRLMs
from three European hepatopancreatobiliary centers
(Girona, Spain; Strasburg, France; Zurich, Switzerland)
between July 2005 and December 2007 were retrospec-
tively assessed for eligibility using well established
databases in each respective center. Forty-five consecutive
patients treated with neoadjuvant chemotherapy with Bev
were identified. An independent reviewer (M.P.) matched
these patients manually by screening a database from 2007
one-by-one against patients who had received neoadjuvant
chemotherapy without Bev. Matching criteria were age,
number of chemotherapeutic cycles, number of metastases,
size of metastases, bilobularity of the disease, synchronous
or metachronous metastases, presence of extrahepatic dis-
ease, simultaneous or staged hepatectomy, and associated
extrahepatic procedures. Results were statistically adjusted
according to potential confounders (\ClinicalTrials.gov[
NCT 00875147).
Outcome measures
Data on outcome parameters were reviewed and extracted
from the prospective database at each center. The primary
endpoint was the occurrence of postoperative complica-
tions, graded according to a validated therapy-oriented
complication score on a five-point scale [26]. Severe
complications were defined as events requiring interven-
tion under local or general anesthesia or treatment in the
intensive care unit (ICU) (complication grade C 3a). Spe-
cific hepatic complications (e.g., subphrenic abscess, bile
leak, bilioma, liver insufficiency) were recorded in detail.
Postoperative liver insufficiency was defined according to
the 50–50 criterion—prothrombin time \50% of normal
and serum bilirubin[50 lmol/l—on postoperative day 5 or
thereafter [27] independent of ascites or encephalopathy.
Preoperative chemotherapy
Preoperative chemotherapy was based on various combi-
nations of chemotherapeutic drugs such as oxaliplatin, iri-
notecan, leucovorin, and 5-FU or capecitabine with or
without Bev. Usually, Bev was given in addition to standard
chemotherapy regimens such as FOLFOX (5-FU/leucov-
orin/oxaliplatin) and FOLFIRI (5-FU/leucovorin/irinote-
can). The number of cycles of neoadjuvant chemotherapy
and the duration of the ‘‘drug holiday’’ were recorded.
Surgical procedure
An R0 resection was targeted in all patients. Pringle’s
maneuver was not applied on a routine basis but was used
selectively according to criteria available at each center.
Intraoperative ultrasonography was performed on a regular
basis in each patient to detect occult tumors and to confirm
the anatomic relations between the tumor and vascular
structures. During major hepatectomy—defined as a resec-
tion of C3 segments [28, 29]—a selective devascularization
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technique was used at the three centers consisting of selec-
tive ligature of the hepatic artery and the portal system prior
to transection of the parenchyma, with the hepatic vein
usually being closed after transection. Liver resection was
carried out using either an ultrasonic surgical dissector
(Girona and Strasbourg) or the crush clamp technique and
bipolar irrigated cautery (Zurich). Biliary and vascular
structures were secured by sutures and clips during hepatic
parenchymal transection.
Statistical analysis (comparability of the groups)
Student’s t-test and the Mann–Whitney test were used to
compare continuous variables with normal and nonnormal
distributions, respectively. The chi-squared test was
applied for comparison between categoric variables.
We compared complication rates using a logistic regres-
sion analysis with complications as a dependent variable and
neoadjuvant chemotherapy (with or without Bev) as an
independent variable. We repeated the analysis for patients
with and without a drug holiday (C6 weeks or\6 weeks).
Odds ratios (ORs) and corresponding 95% confidence
intervals (CIs) were estimated; and p \ 0.05 was considered
statistically significant.
Because this study was not a randomized trial, we paid
attention to potential confounders that might influence the
association between complications and Bev treatment. We
compared the groups in terms of their mean propensity
(probability) of developing a severe complication. We used
a logistic backward-selection regression model, entering
factors associated with complications as independent
variables and major complications (grade C 3a) as a
dependent variable. The variables considered were age,
extrahepatic disease, extrahepatic procedure, major/minor
surgery, type of neoadjuvant chemotherapy, and the need
for perioperative transfusion. All variables in the logistic
regression model with an association of p B 0.3 in the
multivariable model were retained. Based on the resulting
regression equation, we calculated the probability of a
severe complication for each patient and the mean proba-
bility for the two groups. The mean ± SD propensity for
developing a severe complication was 28.6 ± 17.2% for
the Bev group and 20.5 ± 16.2% for the control group.
The difference of 8.1% [95% confidence interval (CI) 1.1–
15.1%] was statistically significant (p = 0.024). With this
evidence showing that the two groups were not entirely
comparable (because of not being a randomized trial), we
adjusted the main analysis for the propensity of getting a
severe complication to adjust for this imbalance between
groups [30]. All statistical analyses were performed using
SPSS version 12 software (SPSS, Chicago, IL, USA) and
Windows version 10 software (Stata, College Station, TX,
USA) [31].
Results
Were the two groups comparable?
Among the 478 consecutive patients treated for CRLMs in
the three centers during the study period, 319 (66.7%)
received preoperative chemotherapy. A total of 45 matched
pairs (90 patients) were enrolled in the study. In 45 patients,
chemotherapy was combined with Bev, and in the remain-
ing 45 it was not (control group). Patients’ demographics
(Table 1) showed no significant differences between the
groups except for sex distribution (42% male in the Bev
group vs. 69% male in the control group, p = 0.02).
In the Bev group, irinotecan was used in 32 patients and
oxaliplatin in 11 compared with 34 and 8 patients, respec-
tively, in the control group. 5-FU-based chemotherapy
without irinotecan or oxaliplatin was applied in five patients
only (two in the Bev and three in the control group). Operative
parameters (Table 1) were comparable in the two groups.
Did adding preoperative Bev affect postoperative
morbidity and mortality?
Occurrence of complications in both groups was adjusted
for propensity, and showed no significant difference
(Tables 2, 3). Overall morbidity rate was 56% (Bev) versus
40% (control); adjusted OR 1.74, 95% CI 0.71–4.28;
p = 0.23. Severe complications showed no significant
increase in Bev compared with the control group: 31 vs.
18%, respectively; adjusted OR 1.76, 95% CI 0.60–5.18;
p = 0.31). Likewise, no difference was noted with respect
to hospital stay (15 days in the Bev group versus 13 days in
the control group). Mortality was 0 versus 2 in the Bev and
control groups, respectively. Causes of death entailed
hepatic insufficiency with multiorgan failure.
Did Bev influence postoperative liver insufficiency
or wound complications?
Surprisingly, the incidence of postoperative hepatic insuf-
ficiency was significantly lower in the Bev group. Post-
operative hepatic insufficiency was documented in only
three patients (7%) in the Bev group compared with nine
(20%) in the control group (adjusted OR 0.19, 95% CI
0.04–0.83, p = 0.03). Wound complications were similar
in the two groups (11% in the Bev group vs. 9% in the
control group, p = 1.00) (Table 2).
Did the Bev drug holiday affect postoperative
complications?
The drug holiday prior to hepatic resection was \6 weeks
in 20 patients (44%), whereas 25 patients (56%) were
94 World J Surg (2010) 34:92–100
123
operated on C6 weeks after the last dose of chemotherapy.
Patient characteristics, postoperative outcome, and the
analysis stratified for patients according to the drug holiday
are summarized in Tables 4 and 5.
Patients in the subgroup that had received Bev\6 weeks
before surgery were significantly younger. There was a
trend toward more cycles in the subgroup that received
chemotherapy C6 weeks before surgery (p = 0.06).
Overall postoperative complications were similar in the
two subgroups. Moreover, the occurrence of severe
complications (grade C 3a) was not significantly different.
ORs were also overlapping (1.74 vs. 1.52), suggesting that
the drug holiday did not have a strong effect on the inci-
dence or severity of postoperative complications.
Discussion
This multicenter comparative study evaluated the influence
of bevacizumab on postoperative outcome after liver
Table 1 Patients’
characteristics
Results, unless otherwise stated,
are the number of patients.
Continuous variables are
reported with the median and
interquartile range (25–75%),
and categorical variables are
reported with percentages
Bev bevacizimab, 5-FU 5-
fluorouracil, CEA
carcinoembronic antigen, RBC
red blood cell, PRBCs packed
red blood cells
a Only data from the Bev group
are recorded
Parameter Bev group Control group p
Demographic data
No. of patients 45 45
Age (years) 58 (54–61) 62 (59–65) 0.08
Male patients (no.) 19 (42%) 31 (69%) 0.02
Preoperative chemotherapy
Duration (months) 4 (3.5–4.8) 3.7 (3.3–4.3) 0.38
Cycles (no.) 9 (7–10) 7 (6–8) 0.16
Cycles (no. C6) 30 (67) 22 (49) 0.13
Bev drug holiday (days)a 60 (47–73)
Irinotecan-based 11 (24%) 8 (18%) 0.55
Oxaliplatin-based 32 (71%) 34 (76%)
5-FU-based 2 (4%) 3 (7%)
Metastases
No. 4 (3–5) 6 (3–8) 0.24
Size (cm) (range) 3.3 (2.4–4.2) 3.2 (2.6–3.9) 0.93
Bilobar 29 (64%) 26 (58%) 0.33
Synchronous 15 (33%) 12 (27%) 0.65
CEA [ 50 ng/ml 14 (31%) 21 (47%) 0.13
Extrahepatic disease 20 (44%) 16 (36%) 0.52
Primary tumor
Colon/sigmoid 19 (42%) 12 (27%) 0.27
Rectum 25 (56%) 31(69%)
Stage
Duke A 2 (4%) 1 (2%) 0.38
Duke B 11 (24%) 7 (16%)
Duke C 31 (69%) 32 (71%)
Operative parameters
Simultaneous surgery 8 (18%) 8 (18%) 1.00
Two-staged hepatectomy 6 (13%) 3 (7%) 0.48
Major hepatectomy (no. C3 segments 19 (42%) 25 (56%) 0.29
RF complementary 16 (36%) 14 (31%) 0.82
Pringle maneuver 34 (76%) 34 (76%) 1.00
Ischemia time (min) 27 (20–34) 34 (28–40) 0.10
Associated extrahepatic procedure 17 (38%) 15 (33%) 0.82
Negative hepatic resection margin (cm) 0.5 (0.30–0.81) 0.45 (0.27–0.63) 0.55
Intraoperative blood loss (ml) 523 (399–646) 658 (407–908) 0.33
Perioperative RBC transfusion 12 (27%) 12 (27%) 1.00
Units PRBCs transfused 1 (0–2) 1 (0–2) 0.94
Operating time (min) 248 (224–270) 270 (237–302) 0.26
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resection for CRLM. Overall morbidity and mortality were
not significantly different between patients exposed or not
to Bev, independent of the Bev ‘‘drug holiday’’ prior to
surgery. Surprisingly, the incidence of postoperative liver
insufficiency was significantly lower in the group of
patients treated with Bev. The only two fatal outcomes
occurred in the control group.
We selected a matched pair methodology based on on-
secutive data collection, with adjustment for potential
confounding using a propensity score [30]. Short of a
randomized controlled trial, this methodology is the most
convincing strategy to evaluate the impact of Bev in this
surgical population.
The correlation between the type of chemotherapeutic
agent, liver injury, and clinical outcome after liver resec-
tion for CRLM is currently under intense debate [32–34].
Oxaliplatin has been shown to cause sinusoidal obstructive
syndrome, or blue liver syndrome [35], and irinotecan
contributes to the development of chemotherapy-associated
steatohepatitis (CASH), which manifests as liver steatosis,
lobular inflammation, and ballooning of hepatocytes [15,
36]. However, the recently published largest randomized
controlled trial reported no increase in morbidity upon
application of perioperative chemotherapy prior to liver
resection for resectable metastatic colorectal cancer [37].
Whether the addition of Bev to those regimens adds tox-
icity has remained unclear.
Platelets play a primary role in hemostasis and angio-
genesis as they are the major transporter of VEGF [38].
Blocking VEGF in platelets by a new chemotherapeutic
drug such as Bev may impair wound healing and promote
gastrointestinal perforations, hemorrhage, and thrombo-
embolic adverse effects [11, 39, 40]. However, the avail-
able clinical data have not convincingly demonstrated
enhancement of postoperative complications by Bev after
either colorectal or liver surgery [40, 41]. Chemotherapy-
associated hepatotoxicity has been mostly linked to the
dose and/or number of treatment cycles [5, 16].
Patient survival has been shown to be markedly
improved when Bev is added to 5-FU-based chemotherapy
regimens (FOLFOX or FOLFIRI) as first-line treatment of
metastatic colorectal cancer [12, 42]. Scappaticci et al. [40]
Table 2 Postoperative complications
Parameter Bev group Control group p
No. of patients 45 45
Outcome
Mortality 0 2 (4%) 0.49
Morbidity 25 (56%) 18 (40%) 0.20
Severe complication (grade C 3a) 14 (31%) 8 (18%) 0.22
Hepatic insufficiency 3 (7%) 9 (20%) 0.03
Hepatobiliary complications 10 (22%) 12 (27%) 0.80
Wound complication 5 (11%) 4 (9%) 1.00
Bleeding/thromboembolic complication 3 (7%) 4 (9%) 1.00
Gastrointestinal complicationb 1 (2%) 1 (2%) 1.00
Hospital stay (days) (range) 15 (11–20) 13 (8–18) 0.47
Unless otherwise stated, the results are the number of patients. Continuous variables are reported with medians and interquartile range (25–75%),
and categorical variables are reported with percentages
a Complication category [26]
b Anastomotic dehiscence or leak
Table 3 Postoperative complications
Characteristics Bev group Control group Unadjusted odds ratio (95% CI) Adjusted odds ratioa
Overall complications 25 (56%) 18 (40%) 1.88 (0.81–4.36), p = 0.14 1.74 (0.71–4.28), p = 0.23
Complications grade C 3a 14 (31%) 8 (18%) 2.09 (0.78–5.63), p = 0.15 1.76 (0.60–5.18), p = 0.31
Hepatobiliary complications 10 (22%) 12 (27%) 0.59 (0.22–1.63), p = 0.31 0.52 (0.18–1.49), p = 0.22
Hepatic insufficiency 3 (7%) 9 (20%) 0.29 (0.07–1.14), p = 0.08 0.19 (0.04–0.83), p = 0.03
Results are the number of patients
CI confidence interval
a Adjusted for propensity of getting complication
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failed to show an increased incidence of wound healing [40]
after primary colorectal cancer resection. Similarly, after
hepatic resection we found no significant difference in
overall wound complications in the Bev group (11%)
compared with the control group (9%). Three studies have
looked at the effects of irinotecan- or oxaliplatin-based
chemotherapy prior to resection of colorectal liver metas-
tases with and without Bev [22–24]. The first study by
D’Angelica et al. [22] was a case-matched study, comparing
patients who received Bev or not preoperatively. This study,
however, suffers from a low number of patients (only 16
patients received Bev preoperatively), a lack of information
regarding the type of chemotherapy used in the control
group, and a lack of data regarding the severity of the
complications. Finally, the outcome values were not
adjusted statistically according to potential confounders.
Table 4 ‘‘Bevacizumab drug
holiday’’: comparison of
\6 weeks or C6 weeks
between hepatectomy and last
dose
Unless otherwise stated, the
results are the number of
patients. Continuous variables
are reported with medians and
interquartile range (25–75%)
and categorical variables are
reported with percentages
a Two patients treated with
capecitabine
b Complication category
according to Dindo et al. [26]
c Anastomotic dehiscence or
leak
Parameter \ 6 Weeks C6 Weeks p
Demographic data
No. of patients 20 25
Age (years) 53 (48–58) 61(57–65) 0.012
No. with age [ 70 years 2 (10%) 7 (28%) 0.26
Male patients 7 (35%) 12 (48) 0.54
Preoperative chemotherapy
Duration (months) 3.6 (2.6–4.6) 4.5 (3.5–5.5) 0.17
Cycles C6 10 (50%) 20 (80%) 0.056
Preoperative irinotecana 14 (70%) 18 (72%) 0.73
Metastases
Hepatic metastasis C4 8 (40%) 9 (36%) 1.00
Bilobular presentation 13 (65%) 16 (64%) 1.00
Synchronous presentation 8 (40%) 7 (28%) 0.52
Extrahepatic disease 10 (50%) 10 (40%) 0.57
Operative parameters
Simultaneous surgery 3 (15%) 5 (20%) 0.71
Two staged hepatectomy 4 (20%) 2 (8%) 0.38
Major hepatectomy (C3 segments) 9 (45%) 10 (40%) 0.77
Associated extrahepatic procedure 8 (40%) 9 (45%) 1.00
Outcome
Intraoperative blood loss (ml) 454 (226–642) 557 (404–750) 0.32
Perioperative RBC transfusions 5 (25%) 7 (28%) 1.00
Overall complications 11 (55%) 14 (56%) 1.00
Complication grade C3ab 6 (30%) 8 (32%) 1.00
All hepatic complications 6 (30%) 5 (20%) 0.50
Liver insufficiency 3 (15%) 3 (12%) 1.00
Wound complication 3 (15%) 2 (8%) 0.64
Bleeding/thromboembolic complications 0 3 (12%) 0.24
Gastrointestinal complicationsc 1 (5%) 0 0.44
Length of hospital stay (days) 14 (8-21) 15 (9-21) 0.90
Mortality 0 0 –
Table 5 Impact of drug holiday on postoperative complications (complication grade C3a)
Condition No. Unadjusted odds ratio (95% CI) Adjusted odds ratioa
Bev subgroup: drug holiday \6 weeks
Bev subgroup: drug holiday C6 weeks
Control group
6 (30%) 1.68 (0.74-3.85), p = 0.22 1.74 (0.70-4.31), p = 0.23
8 (32%) 1.91 (0.73-4.99), p = 0.19 1.52 (0.52-4.48), p = 0.44
8 (18%)
The control group was used for comparisons in both patient groups
a Adjusted for propensity of getting complication and control group
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The second study, by Reddy et al. [23], enrolled 39 patients
treated with Bev, but the results were not statistically
adjusted to confounders. The third study, by Kesmodel et al.
[24], was the largest study with 81 patients included in the
Bev group. However they did not match the control group,
nor did they adjust for confounders. In all three studies
[22–24], Bev was added predominantly to oxaliplatin, as
this is the standard regimen in North America (Table 6).
In the current study, Bev-treated patients had a higher
rate of overall complications and severe complications.
However, the differences did not reach statistical signifi-
cance. We observed a potential advantage in the use of Bev
with the significantly reduced incidence of postoperative
hepatic insufficiency in patients receiving Bev prior to
surgery. The explanation for this benefit is yet unclear, but
we speculate that Bev decreases the sinusoidal injury
induced by oxaliplatin. The observation by others that Bev
decreases the incidence of sinusoidal obstruction syndrome
[17] supports this idea. The exact mechanism of this find-
ing is still unknown, but the VEGF blockade may act by
down-regulating metalloproteinases and thereby decrease
the rate of apoptosis in endothelial cells.
It is currently recommended and accepted by many
groups [19] that liver surgery should be delayed for
6 weeks after the last dose of Bev. The basis of this rec-
ommendation lies in the long half-life (*20 days) of the
drug [8, 43]. Some groups have looked at this more care-
fully. For example, Gruenberger et al. [41] reported that
Bev can be safely administered up to 5 weeks before liver
resection [41], whereas recently Reddy et al. [23] recom-
mended discontinuation of Bev at least 8 weeks prior to
surgery [23]. In our study, we failed to identify any sig-
nificant impact on the occurrence of postoperative com-
plications in patients who had received Bev\6 weeks or in
those who had taken Bev C6 weeks before liver resection.
However, caution must be applied because of the relatively
small number of patients (n = 20) who had received Bev
shortly prior to surgery. Until confirmation of these data,
we still discontinue Bev at least 4 weeks prior to surgery in
each of our centers.
The main limitation of this study was the retrospective
nature of the analysis. Despite the fact that unadjusted and
carefully adjusted analyses did not differ markedly, we
cannot exclude substantial residual confounding factors.
A second limitation is the acquisition of data from three
centers in Europe. Differences regarding technical details
during surgery data collection may lead to heterogeneity of
data. However, these three European centers have a large
experience with and volume of liver surgery, and they use
comparable liver resection techniques. These potential
shortcomings were addressed by case matching and
adjusting for the propensity to develop complications. As a
final point, we cannot exclude the possibility that with a
larger group of patients the slight differences in the com-
plication rate might become significant.
Conclusions
This study provides evidence that Bev, in combination with
modern neoadjuvant chemotherapies, does not significantly
increase the number or the severity of postoperative com-
plications. The discontinuation of Bev therapy C6 weeks
prior to surgery may not confer any reduction in morbidity
after liver resection. If the potential benefit of Bev in pre-
venting postoperative liver failure is confirmed, Bev may
enjoy an increased interest in its use as neoadjuvant che-
motherapy prior to resection for colorectal liver metastasis.
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